Super Hi International Holding Ltd., operator of Haidilao hot pot restaurants internationally, will release its unaudited financial results for Q3 2026 on November 25 before U.S. market open. The company will hold an earnings call at 7:00 AM ET to discuss the results, accessible via live webcast in English and Chinese. Haidilao is a globally recognized Chinese cuisine brand with 129 restaurants across 14 countries as of mid-2026. Investors can expect insights into the company's recent performance and outlook during the call.
Super Hi International Holding Ltd.'s upcoming Q3 2026 financial results provide context for market watchers. For readers following the Consumer Cyclical sector, here is Pluang's market snapshot as of Nov 13, 2026 17:01 WIB: Of 134 priced US stocks, 65 rose and 52 fell. Notable movers include NEGG at USD 8.80 with a 1-day change of +1.73% and 100% buy order activity, HMC at USD 34.07 with a 1-day change of +1.61% and a typical hold time of 7 days, and LOW at USD 223.88 with a 1-day change of -1.60% and a typical hold time of 92 days.
The Philippines solar energy market is projected to grow from 5.43 GW in 2026 to 23.35 GW by 2032, with a CAGR of 27.46%. Growth is fueled by declining costs of solar panels and installation, government-backed renewable energy auctions, and increasin...
Equinor ASA shares will trade ex-dividend on the Oslo Stock Exchange starting November 13, 2026, for the second quarter of 2026. The declared dividend amount is $0.39 per share, payable in USD. This means investors buying shares from this date will n...
China Eastern Airlines signed 23 procurement agreements worth $540 million with 15 suppliers from eight countries at the 9th China International Import Expo in Shanghai. The deals cover aircraft engines, aviation materials, jet fuel, and in-flight ca...
Eramet announced a €500 million share capital increase through a rights issue, offering 6 new shares for every 5 existing shares at €14.49 each. The proceeds will be used to reduce the company's debt and strengthen its balance sheet as part of a prev...
Pasithea Therapeutics announced positive Phase 1/1b results for PAS-004, showing significant reductions in cutaneous neurofibromas (cNF) size by up to 71% with continued treatment and early activity in plexiform neurofibromas (PN). The drug demonstra...
